AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2115446 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution (100 mg flecainide)
Number of subjects: 7
Study 2115446 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet (100 mg flecainide)
Number of subjects: 7
Study 7002205 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine (long infusion)
Number of subjects: 0
Study 7002205 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine (short infusion)
Number of subjects: 0
Study 7002205 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine (intramuscular injection)
Number of subjects: 0
Study 7002205 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (bed rest and sedatives)
Number of subjects: 0
Study 7002205 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritodrine (all regimens)
Number of subjects: 0
Study 30693742 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing intervention
Number of subjects: 100
Study 30693742 — intervention group
Group type: COMPARATOR
Intervention: Conventional nursing care
Number of subjects: 100
Study 28864689 — intervention group
Group type: EXPERIMENTAL
Intervention: Managed aquifer recharge (MAR) water consumption
Number of subjects: 16
Study 28864689 — intervention group
Group type: COMPARATOR
Intervention: Brackish groundwater
Number of subjects: 16
Study 25935174 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided PCI
Number of subjects: 123
Study 25935174 — intervention group
Group type: COMPARATOR
Intervention: Control group (angiography-guided PCI)
Number of subjects: 123
Study 24347261 — intervention group
Group type: EXPERIMENTAL
Intervention: Blunt technique
Number of subjects: 1076
Study 24347261 — intervention group
Group type: COMPARATOR
Intervention: Sharp technique
Number of subjects: 1076
Study 21416547 — intervention group
Group type: EXPERIMENTAL
Intervention: Submandibular salivary gland transfer (SGT)
Number of subjects: 69
Study 21416547 — intervention group
Group type: COMPARATOR
Intervention: Oral pilocarpine
Number of subjects: 69
Study 19716007 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical sucralfate
Number of subjects: 82
Study 19716007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 17729016 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100-400 mg/day or 200 mg/day)
Number of subjects: 348
Study 17729016 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 348
Study 15269315 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 141
Study 15269315 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 15269315 — intervention group
Group type: EXPERIMENTAL
Intervention: Valacyclovir
Number of subjects: 141
Study 15269315 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone plus valacyclovir
Number of subjects: 141
Study 12167574 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and 5-Fluorouracil chemotherapy (pulse regimen)
Number of subjects: 83
Study 12167574 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and 5-Fluorouracil chemotherapy (continuous infusion regimen)
Number of subjects: 83
Study 12167574 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone (historical control)
Number of subjects: 83
Study 10474398 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visit interventions by school nurses and bilingual teachers
Number of subjects: 0
Study 10474398 — intervention group
Group type: COMPARATOR
Intervention: No intervention (comparison group)
Number of subjects: 0
Study 7712759 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of famotidine (1.7 mg/hr for 24 hrs)
Number of subjects: 0
Study 7712759 — intervention group
Group type: COMPARATOR
Intervention: Bolus administration of famotidine (20 mg i.v. over 10 mins, every 12 hrs)
Number of subjects: 0
Study 1506045 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mL of 16.5% immune serum globulin (ISG)
Number of subjects: 76
Study 1506045 — intervention group
Group type: COMPARATOR
Intervention: 2 mL of normal saline
Number of subjects: 76
Study 6522905 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy (PGV)
Number of subjects: 38
Study 6522905 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal gastric vagotomy and pyloroplasty (PGV + P)
Number of subjects: 38
Study 6522905 — intervention group
Group type: EXPERIMENTAL
Intervention: Total gastric vagotomy (TGV)
Number of subjects: 38
Study 6522905 — intervention group
Group type: EXPERIMENTAL
Intervention: Total gastric vagotomy and pyloroplasty (TGV + P)
Number of subjects: 38
Study 30439560 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement with attractive female peer on social media (n=56)
Number of subjects: 118
Study 30439560 — intervention group
Group type: COMPARATOR
Intervention: Engagement with family member on social media (n=62)
Number of subjects: 118
Study 29851803 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser acupuncture (LA) plus conventional treatment
Number of subjects: 200
Study 29851803 — intervention group
Group type: COMPARATOR
Intervention: Sham laser acupuncture (LA without laser output) plus conventional treatment
Number of subjects: 200
Study 26924099 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized reminder intervention (customized letter and personal telephone outreach)
Number of subjects: 256
Study 26924099 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 256
Study 26924099 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of the intervention
Number of subjects: 256
Study 24332934 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational cues every 2 hours with advice on how to improve activity, on top of real-time visual feedback.
Number of subjects: 15
Study 22099477 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin and standard analgesia
Number of subjects: 61
Study 22099477 — intervention group
Group type: COMPARATOR
Intervention: Placebo and standard analgesia
Number of subjects: 61
Study 20606402 — intervention group
Group type: COMPARATOR
Intervention: High-dose adecatumumab (6 mg/kg)
Number of subjects: 0
Study 20606402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20606402 — intervention group
Group type: COMPARATOR
Intervention: Low-dose adecatumumab (2 mg/kg)
Number of subjects: 0
Study 17500020 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral co-trimoxazole for 3 months
Number of subjects: 20
Study 17500020 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 20
Study 16640635 — intervention group
Group type: EXPERIMENTAL
Intervention: Periosteal graft group (n = 15)
Number of subjects: 30
Study 16640635 — intervention group
Group type: COMPARATOR
Intervention: Bioabsorbable membrane group (n = 15)
Number of subjects: 30
Study 16640635 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study 15012690 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 200 mg daily for 8 weeks
Number of subjects: 73
Study 15012690 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/day for 8 weeks
Number of subjects: 73
Study 11058789 — intervention group
Group type: COMPARATOR
Intervention: Polymorphisms in the alpha-2 macroglobulin gene (5 bp deletion and G/A point mutation)
Number of subjects: 238
Study 11058789 — intervention group
Group type: COMPARATOR
Intervention: Polymorphisms in the alpha-2 macroglobulin gene (5 bp deletion and G/A point mutation) combined with APOE varepsilon4 genotype
Number of subjects: 238
Study 9304162 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment
Number of subjects: 605
Study 9304162 — intervention group
Group type: COMPARATOR
Intervention: No thrombolytic treatment
Number of subjects: 605
Study 9304162 — intervention group
Group type: EXPERIMENTAL
Intervention: CAVB presence
Number of subjects: 605
Study 8471229 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 40
Study 8471229 — intervention group
Group type: COMPARATOR
Intervention: Nicardipine
Number of subjects: 40
Study 3578970 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic antishock garment (PASG)
Number of subjects: 201
Study 3578970 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PASG)
Number of subjects: 201
Study 30038198 — intervention group
Group type: EXPERIMENTAL
Intervention: Buzzy System with distraction cards
Number of subjects: 72
Study 30038198 — intervention group
Group type: COMPARATOR
Intervention: Magic gloves
Number of subjects: 72
Study 27874837 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritist Passe (SP)
Number of subjects: 72
Study 27874837 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72
Study 27874837 — intervention group
Group type: COMPARATOR
Intervention: No-SP group (nonspiritual therapy)
Number of subjects: 72
Study 24553973 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Montelukast
Number of subjects: 60
Study 24553973 — intervention group
Group type: COMPARATOR
Intervention: Inhaled Budesonide
Number of subjects: 60
Study 22628060 — intervention group
Group type: EXPERIMENTAL
Intervention: EDOX+ENOX
Number of subjects: 0
Study 22628060 — intervention group
Group type: EXPERIMENTAL
Intervention: ENOX
Number of subjects: 0
Study 22628060 — intervention group
Group type: EXPERIMENTAL
Intervention: ENOX12-EDOX
Number of subjects: 0
Study 22628060 — intervention group
Group type: EXPERIMENTAL
Intervention: EDOX
Number of subjects: 0
Study 20448541 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (‐T, ‐E)
Number of subjects: 54
Study 20448541 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (‐T, +E)
Number of subjects: 54
Study 20448541 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (+T, ‐E)
Number of subjects: 54
Study 20448541 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (+T, +E)
Number of subjects: 54
Study 17376119 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate treatment
Number of subjects: 67
Study 17376119 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 15721970 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored advice for hypertension management
Number of subjects: 767
Study 15721970 — intervention group
Group type: COMPARATOR
Intervention: General health promotion advice
Number of subjects: 767
Study 12194619 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding a weighted spoon (248 g)
Number of subjects: 16
Study 12194619 — intervention group
Group type: COMPARATOR
Intervention: Holding a built-up spoon (108 g)
Number of subjects: 16
Study 12194619 — intervention group
Group type: EXPERIMENTAL
Intervention: Holding a built-up spoon while wearing a weighted wrist cuff (470 g)
Number of subjects: 16
Study 7880662 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltanolone 4 mg ml‐1 administered at a rate of 300 ml h‐1
Number of subjects: 30
Study 7880662 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltanolone 4 mg ml‐1 administered at a rate of 600 ml h‐1
Number of subjects: 30
Study 7880662 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltanolone 4 mg ml‐1 administered at a rate of 1200 ml h‐1
Number of subjects: 30
Study 2975925 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil
Number of subjects: 20
Study 2975925 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 20
Study 31222771 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperinsulinaemia and insulin resistance (IR)
Number of subjects: 1000
Study 26873293 — intervention group
Group type: EXPERIMENTAL
Intervention: Live interactive training
Number of subjects: 63
Study 26873293 — intervention group
Group type: COMPARATOR
Intervention: Web-facilitated self-study training
Number of subjects: 63
Study 25130167 — intervention group
Group type: EXPERIMENTAL
Intervention: Kegel exercises with vaginal spheres, performed twice daily, 5 days/week for 6 months.
Number of subjects: 70
Study 25130167 — intervention group
Group type: COMPARATOR
Intervention: Kegel exercises without vaginal spheres (control group), performed twice daily, 5 days/week for 6 months.
Number of subjects: 70
Study 25130167 — intervention group
Group type: EXPERIMENTAL
Intervention: Kegel exercises with vaginal spheres.
Number of subjects: 70
Study 25130167 — intervention group
Group type: COMPARATOR
Intervention: Kegel exercises without vaginal spheres (control group).
Number of subjects: 70
Study 23581277 — intervention group
Group type: EXPERIMENTAL
Intervention: Picosulphate/magnesium citrate (Group 1)
Number of subjects: 285
Study 23581277 — intervention group
Group type: COMPARATOR
Intervention: PEG + ASC (Group 2)
Number of subjects: 285
Study 22122814 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen sodium dihydrate 400 mg
Number of subjects: 144
Study 22122814 — intervention group
Group type: COMPARATOR
Intervention: Conventional ibuprofen 400 mg
Number of subjects: 144
Study 19168461 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) or brain natriuretic peptide (BNP) as a diuretic
Number of subjects: 272
Study 19168461 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 272
Study 19168461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 16765532 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous L-alanyl-L-glutamine 0.4 g/kg weight/day
Number of subjects: 29
Study 16765532 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 29
Study 15288394 — intervention group
Group type: EXPERIMENTAL
Intervention: SA‐CST + ET
Number of subjects: 72
Study 15288394 — intervention group
Group type: EXPERIMENTAL
Intervention: ET alone
Number of subjects: 72
Study 15288394 — intervention group
Group type: EXPERIMENTAL
Intervention: SA‐CST alone
Number of subjects: 72
Study 15288394 — intervention group
Group type: COMPARATOR
Intervention: SC
Number of subjects: 72
Study 11736859 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide (100 mg capsules) for 14 days
Number of subjects: 50
Study 11736859 — intervention group
Group type: COMPARATOR
Intervention: Intravenous etoposide (50 mg) on day 1 or day 7
Number of subjects: 50
Study 9416715 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine thermal management (hypothermia)
Number of subjects: 150
Study 9416715 — intervention group
Group type: COMPARATOR
Intervention: Extra warming (normothermia)
Number of subjects: 150
Study 7848388 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms of fentanyl in 2 ml volume added to 0.5% bupivacaine
Number of subjects: 90
Study 7848388 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of fentanyl in 2 ml volume added to 0.5% bupivacaine
Number of subjects: 90
Study 7848388 — intervention group
Group type: COMPARATOR
Intervention: 2 ml of saline added to 0.5% bupivacaine
Number of subjects: 90
Study 3168642 — intervention group
Group type: EXPERIMENTAL
Intervention: Sad affect induction
Number of subjects: 125
Study 3168642 — intervention group
Group type: EXPERIMENTAL
Intervention: Angry affect induction
Number of subjects: 125
Study 31232112 — intervention group
Group type: EXPERIMENTAL
Intervention: BsmI polymorphism (Bb and bb)
Number of subjects: 70
Study 31232112 — intervention group
Group type: COMPARATOR
Intervention: FokI polymorphism
Number of subjects: 70
Study 30954086 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy (PBMT)
Number of subjects: 200
Study 30954086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 28592454 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated-platelet levels ≥51.1%
Number of subjects: 171
Study 28592454 — intervention group
Group type: EXPERIMENTAL
Intervention: Coated-platelet model
Number of subjects: 171
Study 26700275 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring of blood glucose, blood pressure, and weight
Number of subjects: 33
Study 26700275 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring of blood glucose
Number of subjects: 33
Study 26700275 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemonitoring
Number of subjects: 33
Study 26700275 — intervention group
Group type: EXPERIMENTAL
Intervention: Home monitoring convenience
Number of subjects: 33
Study 22812691 — intervention group
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 600 mg on days 1-3 and 1,200 mg on days 4-9, once daily
Number of subjects: 14
Study 22812691 — intervention group
Group type: COMPARATOR
Intervention: Oxcarbazepine (OXC) 300 mg on days 1-3 and 600 mg on days 4-9, twice daily
Number of subjects: 14
Study 22729520 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative lymphatic mapping and sentinel node biopsy
Number of subjects: 0
Study 22729520 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 19419555 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlexanox oral adhesive pellicles
Number of subjects: 216
Study 19419555 — intervention group
Group type: COMPARATOR
Intervention: Amlexanox oral adhesive tablets
Number of subjects: 216
Study 19419555 — intervention group
Group type: COMPARATOR
Intervention: Placebo pellicles
Number of subjects: 216
Study 17466972 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-desamino-8-D-arginine-vasopressin administration after water loading
Number of subjects: 20
Study 17466972 — intervention group
Group type: COMPARATOR
Intervention: Water loading
Number of subjects: 20
Study 15095796 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent bathing under nursing supervision at the bedside
Number of subjects: 111
Study 15095796 — intervention group
Group type: COMPARATOR
Intervention: Nurse bathing in an admission nursery
Number of subjects: 111
Study 11231774 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 20968
Study 11231774 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent aspirin use (>/=180 days per year)
Number of subjects: 20968
Study 9576406 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg/day)
Number of subjects: 22
Study 9576406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 7935702 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (40 mg orally twice daily)
Number of subjects: 404
Study 7935702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 404
Study 3428345 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg capsule
Number of subjects: 20
Study 3428345 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg i.v.
Number of subjects: 20
Study 3428345 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg capsule
Number of subjects: 20
Study 3428345 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg suspension
Number of subjects: 20
Study 31930293 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 0
Study 31930293 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 0
Study 31930293 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study 29728882 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate glue with low-weight polypropylene mesh (n=216)
Number of subjects: 625
Study 29728882 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-absorbable sutures with partially absorbable mesh (n=207)
Number of subjects: 625
Study 29728882 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-gripping polyesther mesh (n=202)
Number of subjects: 625
Study 29728882 — intervention group
Group type: COMPARATOR
Intervention: All groups combined
Number of subjects: 625
Study 28623904 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MM)
Number of subjects: 5011
Study 28623904 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA)
Number of subjects: 5011
Study 28623904 — intervention group
Group type: COMPARATOR
Intervention: Folic acid (FA)
Number of subjects: 5011
Study 26394355 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-deantigenic equine bone (EDEB)
Number of subjects: 40
Study 26394355 — intervention group
Group type: COMPARATOR
Intervention: Anorganic bovine bone (ABB)
Number of subjects: 40
Study 26394355 — intervention group
Group type: COMPARATOR
Intervention: Both EDEB and ABB
Number of subjects: 40
Study 23149081 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy assessment before first infusion
Number of subjects: 91
Study 23149081 — intervention group
Group type: COMPARATOR
Intervention: No expectancy assessment (control group)
Number of subjects: 91
Study 23149081 — intervention group
Group type: EXPERIMENTAL
Intervention: Expectancy assessment
Number of subjects: 91
Study 21681585 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg BGC20-1531
Number of subjects: 8
Study 21681585 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg BGC20-1531
Number of subjects: 8
Study 21681585 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 18365505 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical sphincterotomy
Number of subjects: 60
Study 18365505 — intervention group
Group type: COMPARATOR
Intervention: Botulinum toxin injections into internal anal sphincter
Number of subjects: 60
Study 17052565 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen extended release 1,300 mg 3 times daily
Number of subjects: 260
Study 17052565 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen 400 mg 3 times daily
Number of subjects: 260
Study 12747651 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 ml (12.5 mg) triamcinolone acetonide intravitreally
Number of subjects: 31
Study 12747651 — intervention group
Group type: COMPARATOR
Intervention: 0.3 ml balanced salt solution after retrobulbar anesthesia
Number of subjects: 31
Study 11149273 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa antagonists (abciximab, tirofiban, eptifibatide)
Number of subjects: 0
Study 8636902 — intervention group
Group type: EXPERIMENTAL
Intervention: Repressive personality and social behavior
Number of subjects: 0
Study 8636902 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological distancing under threat
Number of subjects: 0
Study 8636902 — intervention group
Group type: EXPERIMENTAL
Intervention: Processing self-relevant and non-self-relevant information
Number of subjects: 0
Study 1592715 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine/Lysine supplementation (AL)
Number of subjects: 30
Study 1592715 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 30